Sidley Represents Keymed Biosciences in US$1.1 Billion Partnership With AstraZeneca and Lepu Biopharma

Sidley represented Keymed Biosciences, a China-based, publicly traded biopharmaceutical company in the out-licensing of CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC) to AstraZeneca (NASDAQ: AZN). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture, and commercialization of CMG901 globally.

Under the terms of the agreement, KYM Biosciences, the joint venture established by Keymed and Lepu Biopharma, will receive an upfront payment of US$63 million on transaction closing and additional development and sales-related milestone payments of up to US$1.1 billion, as well as tiered royalties of up to low double-digits. The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.

The Sidley team was led by James Lu (Emerging Companies and Venture Capital), Stephen Abreu, and Longbo Wang (Technology and Life Sciences Transactions), and Ed Sharon (Antitrust/Competition), and includes Cassidy Pomeroy-Carter and Ashleigh Lussenden (Technology and Life Sciences Transactions); William Blumenthal and Jason Semmes (Antitrust/Competition); Oliver Zhong (Capital Markets); Emma Ballard (Commercial Litigation and Disputes); Scott Nonaka (Global Arbitration, Trade and Advocacy); Cynthia Bai (Global Finance); and Pan Chen (M&A).

Additional details are available in the press release.

About Sidley Austin

Sidley is an elite global law firm with nearly US$3 billion in revenue powered by lawyers who practice at the highest level of the profession. Backed by 156 years of trailblazing heritage, we deliver superior service to a high-caliber group of market leaders worldwide, while placing a premium on collaboration and diversity. Our firm boasts a roster of more than 2,300 lawyers who wield deep experience in litigation, transactional and regulatory matters spanning over 50 legal disciplines and industries. With 21 offices situated in major commercial and financial capitals around the world, our lawyers possess the cultural awareness and legal acumen needed to advise clients in today’s global economy. We are “Built to Win.”

Our offices are found in Beijing, Boston, Brussels, Century City, Chicago, Dallas, Geneva, Hong Kong, Houston, London, Los Angeles, Miami, Munich, New York, Palo Alto, San Francisco, Shanghai, Singapore, Sydney, Tokyo, and Washington, D.C.